Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

ARO-ALK7

Oligonucleotide (siRNA) · Gene silencing: ALK7 (ACVR1C) · developed by ARROWHEAD PHARMACEUTICALS

Phase 1/2 Most advanced trial
ARWR Developer
1 Registered trials

What is ARO-ALK7?

ARO-ALK7 is an siRNA therapeutic that silences ALK7 (ACVR1C). It is administered by subcutaneous injection and is being studied in obesity and type 2 diabetes mellitus.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Oligonucleotide (siRNA)
Targets
ALK7 (ACVR1C)
Mechanism
Gene silencing: ALK7 (ACVR1C)
Therapy area
Endocrine, Metabolic
Developer
ARROWHEAD PHARMACEUTICALS (ARWR)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06937203 Phase 1/2 Obesity Recruiting ARWR

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Diabetes Mellitus, Type 2Obesity

More from ARROWHEAD PHARMACEUTICALS

Plozasiran FDA approved ARC-521 Phase 1 ARC-AAT Phase 2 ARO-033 Phase 1 ARO-ANG 3 Phase 2 ARO-APOC3 Phase 2 ARO-ATXN2 Phase 1 ARO-C3 Phase 1/2 ARO-CFB Phase 1 ARO-DIMERPA Phase 1/2 ARO-ENaC Phase 1/2 ARO-HBV Phase 1/2

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the ARWR page.

Follow ARWR, the company behind ARO-ALK7

See ARWR's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

ARWR catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.